Stem cell therapies have shown promise in promoting recovery in stroke but have been limited by poor cell survival and differentiation. We have developed a hyaluronic acid (HA)-based selfpolymerizing hydrogel that serves as a platform for adhesion of structural motifs and a depot release for growth factors to promote transplant stem cell survival and differentiation. We took an iterative approach in optimizing the complex combination of mechanical, biochemical and biological properties of an HA cell scaffold. First, we optimized stiffness for a minimal reaction of adjacent brain to the transplant. Next hydrogel crosslinkers sensitive to matrix metalloproteinases (MMP) were incorporated as they promoted vascularization. Finally, candidate adhesion motifs and growth factors were systemically changed in vitro using a design of experiment approach to optimize stem cell survival or proliferation. The optimized HA hydrogel, tested in vivo, promoted survival of encapsulated human neural progenitor cells (iPS-NPCs) after transplantation into the stroke core and differentially tuned transplanted cell fate through the promotion of glial, neuronal or immature/progenitor states. This HA hydrogel can be tracked in vivo with MRI. A hydrogel can serve as a therapeutic adjunct in a stem cell therapy through selective control of stem cell survival and differentiation in vivo.
Introduction
Stroke is the leading cause of long-term disability [1] . There are no therapies that promote recovery in this disease. New strategies aimed at enhancing post-stroke brain plasticity have utilized trophic factors, stem cell therapies or a combination of the two. However, their clinical translation has been limited because of the short half-life and undesirable systemic effects of injected growth factors [2, 3] and poor survival of transplanted cells [4] , partly due to the abrupt withdrawal of adhesive support and the inflammatory environment of the damaged brain [5] .
Although there are many protocols to differentiate in vitro stem/progenitor cells to desired fates, in vivo these protocols are either not possible or fail to differentiate the cells to the same extent.
The lack of a successful medical therapy that promotes long-term recovery in stroke imposes a substantial clinical and economic burden, indicating the need for a novel therapeutic solution.
Recent advances in tissue engineering have developed injectable hydrogels that can serve both as a protective vehicle for cells and a depot release platform for trophic factors, with distinct synergistic advantages of both strategies. Cell-loaded hydrogels provide structural support that not only directly promote the survival of encapsulated cells [6] , but also promote cell infiltration from the surrounding parenchyma [7] and reduce the glial scar and inflammation at the ischemic border [8, 9] . Similarly, local drug delivery from injectable hydrogels can achieve sustained [3, 10, 11] or sequential delivery [12] in a time-and space-controlled manner, while enhancing protein stability, diffusion distance and in vivo bioactivity [11] . Polymer-based hydrogels are highly customizable as their composition can be modified to adapt to the host tissue. For example, a simple alteration of the polymer length, the crosslinking points and/or the scaffold mesh size can modulate gel stiffness, nutrient diffusion, and even cell motility [13] . Recent studies have shown that a wide variety of chemical, mechanical and spatial cues can be incorporated into cell-material interactions to ultimately allow for greater control over cell behavior [14] .
Hyaluronic acid (HA) gels are appealing choices for cell encapsulation in a transplant approach. HA is abundantly found in the brain, particularly in the endogenous environment for neural progenitor cells (NPCs) [15] and it is both a biocompatible and bioresorbable material that allows cells to degrade it as they spread within the gel [16] . We have previously reported a hyaluronic acid hydrogel crosslinked in situ via thiol/acrylate Michael type addition for human induced pluripotent neural precursor (iPS-NPC) culture in vitro, which demonstrated biocompatibility after transplantation in vivo [13] .
Stroke offers a unique opportunity for a tissue engineering neural repair therapy. After initial cell death in stroke, the clearance of debris in the lesion leaves a compartmentalized cavity that can accept a large volume transplant without further damaging the surrounding healthy parenchyma [17] . This stroke cavity is situated directly adjacent to the peri-infarct tissue, the region of the brain that undergoes the most substantial repair and recovery, meaning that any therapeutic delivered to the cavity will have direct access to the tissue target for repair [2] .
Although utilizing a hydrogel material to promote differentiation of transplanted stem cells is a logical next step, no published study has shown substantial differentiation or differential control over post-transplantation cell fate. We developed a hydrogel material that can control transplanted human neural progenitor cell fate in vivo after the injection through the modulation of adhesive and trophic signals delivered from the scaffold. We show that the material can be optimized in vitro to result in either maintenance of the progenitor state or differentiation towards different central nervous system fates in vivo. Our findings mark the first time a hydrogel has been engineered to control transplanted human stem/progenitor cell fate in vivo utilizing in vitro findings.
Materials and Methods

Cell culture
Induced pluripotent stem cells (iPS) were generated from human fibroblasts and characterized [18] under approved protocols from the UCLA ESCRO. NPCs were differentiated from iPS through formation of neural rosettes and maintained in culture [19] . On the day of transplantation human iPS-NPCs were harvested by TrypLE treatment (3-5 minutes; Life Technologies), centrifuged at 300 g for 5 minutes, re-suspended in maintenance culture medium and kept on ice. Cell viability throughout transplantation process remained above 95%-97% as determined by Trypan blue exclusion method. Animal origin-free products were used for the cell culture.
Hyaluronic acid modification
Hyaluronic acid (60,000 Da, Genzyme, Cambridge, MA) was functionalized with an acrylate group using a two-step synthesis as previously described [20] . After dissolving the HA (2.0 g, 5.28 mmol) in water, it was reacted with adipic dihydrazide (ADH, 18.0 g, 105.5 mmol) in the presence of 1-ethyl-3-(dimethylaminopropyl) carbodiimide hydrochloride (EDC, 4.0 g, 20 mmol) overnight at a pH of 4.75. The hydrazide-modified hyaluronic acid (HA-ADH) was purified with decreasing amounts of NaCl (100, 75, 50, 25 mmol) for 4 hours each via dialysis (8,000 MWCO). The solution was then purified via dialysis (8000 MWCO) in deionized water for 2 days and lyophilized. The HA-ADH was re-suspended in 4-(2-hydroxyethyl)-1-piperazine ethane-sulfonic acid (HEPES) buffer (10 mM HEPES, 150 mM NaCl, 10 mM EDTA, pH 7.4) and reacted with Nacryloxysuccinimide (NHS-AC), 1.33 g, 4.4 mmol) overnight. After purification via dialysis as described earlier, the acrylated HA (HA-AC) was lyophilized. The product was analyzed with 1H NMR (D2O) and the degree of acrylation (14.9%) determined by dividing the multiplet peak at δ = 6.2 (cis and trans acrylate hydrogens) by the singlet peak at δ = 1.6 (singlet peak of acetyl methyl protons in HA). This gel was chosen because of its biocompatibility with human tissue, as it is constituted of naturally occurring brain extracellular matrix constituents. The mechanical properties of this gel are similar to those of normal brain. HA has been shown to promote angiognesis in a mouse model of skin wound healing [21, 22] . Biotin was then introduced to HA-AC using sulfo-NHS-LC-biotin (NHS-biotin). NHS-biotin (100mg) was added as a solid to a solution of HA-AC (300 mg; 3 mg/mL in PBS; pH 7.4) as previously described [22] . The reaction proceeded for 16 hours at room temperature with stirring. The reaction product was then purified by dialysis (MWCO 14,000) against distilled water for 24 hours. The final purified product was lyophilized and stored at 4°C until used.
Heparin modification
Heparin Carboxylic acid groups (Alfa Caesar, Ward Hill, MA) were functionalized with thiol groups by dissolving 2 mg/mL of heparin in PBS. To this solution, EDC, NHS, and an excess amount of cysteamine were added. The pH of the reaction mixture was adjusted to 4.75 and the reaction was allowed to continue overnight with stirring at room temperature. DTT was then added to reduce the oxidized disulfide groups in order to release thiol groups. This solution was allowed to react overnight at pH 7.5 and then adjusted to pH 3.5 by the addition of 1.0 N HCl. Next, the reaction solution was dialyzed and lyophilized. The amount of the thiol group attached to heparin was measured using the molar absorptivity of Ellman's reagent at 412 nm. 
Gelation
Rheometry
Gels without cells were made as described above and cut to size using a 8.0 mm biopsy punch.
The modulus was measured with a plate-to-plate rheometer (Physica MCR 301, Anton Paar, Ashland, VA) using a 8 mm plate with a frequency range of 0.1-10 rad/s under a constant strain of 1% at 37°C. An evaporation blocker system was used to keep the gel from dehydrating during the test. Addition of iPS-NPCs to the HA gel did not change mechanical properties of gels shortly after gelation (Figure 1; [54]) 
Cell survival in vitro
Cell survival was measured using the CyQUANT cell proliferation assay kit (Invitrogen). Gels were washed twice in 1x PBS and frozen in a -80 freezer at days 1 and 7 after gel gelation. After thawing the gels at room temperature, they were degraded by incubation in TrypLE express (Invitrogen) at 37°C for 15 minutes. The cells were isolated by centrifuging the solution at 250 g for 5 minutes and re-suspended in 200 µL of the CyQUANT GR dye/cell-lysis buffer. After 5 minute incubation, the fluorescence was read using a plate reader at 480 nm.
Flow cytometry
Gels at day 1 or 7 after gelation were rinsed in 1x PBS and degraded by pipetting the gel up and down via a 1000 µL pipette. The solution was spun at 250 g for 10 minutes and re-suspended in BD Cytofix (Becton Dickinson, New Jersy) for 30 minutes at room temperature. After spinning down at 250 g for 5 minutes, samples were re-suspended in 1x PBS + 1% bovine serum albumin (BSA, Fisher Scientific) + 0.2% saponin (Sigma-Aldrich) for 15 minutes at room temperature.
Antibodies were then added to the solution for 30 minutes at room temperature. Following a spin at 250 g for 5 minutes, the samples were re-suspended in 1% paraformaldehyde for Fluorescence Activated Cell Sorting (FACS). Analysis was performed using a FACScan X (BD Bioscience, San Jose, CA) and the data was analyzed using FLOWJO (Version 10.0.7; Tree Star Inc, Ashland, OR). Triplicates were done for each condition with 3000 events/sample. The Dcx samples were gated to contain the positive signal peak.
Design of experiments
JMP software (SAS, Cary, NC) was used to generate the gel conditions and to analyze the subsequent data. A surface response methodology (RSM) setup was used to vary the ligands of interest within a specific concentration range using a central composite inscribed design (CCI).
For each iteration, a response surface methodology experiment was developed in which each variable factor was given a defined range (μM) to be modulated within. Here, the Central composite on face, a specific RSM statistical design was chosen, as this system enabled us to test the end points of each factor. Data from the cell survival assay for each condition recommended was inputted back into the software. The data was analyzed via a least squares regression model to determine significance of the factors and plot the predicted response surface. Each condition was done in triplicate and data from gels at day 7 were normalized to gels from the same condition at day 1 to account for any differences in the numbers of cells encapsulated in the gel precursor solution.
Inducing stroke and transplantation
The procedures involving animals and human cells were performed in accordance with National Institutes of Health Animal Protection Guidelines and approved by the UCLA Chancellor's Animal Research Committee as well as the UCLA Office of Environment Health and Safety. A cortical model of photothrombotic stroke was produced in 2-month-old male C57BL/6 (Jackson Laboratory, Bar Harbor, ME) or Nod-Scid-gamma (NSG) mice (Jackson Laboratories). Mice were anesthetized and maintained with 2% isoflurane in N2O:O2 (2:1). Stroke was produced with a light-sensitive dye in a photothrombotic approach as previously described [23] . Briefly, mice were positioned in a stereotaxic instrument and administered Rose Bengal (10 mL/gr from 10 mg/mL solution, i.p.). A 2 mm diameter region of the closed skull was illuminated with a white light for 15 minutes. Temperature was maintained at 37±0.5 °C (RightTemp™, Kent Scientific, Torrington, CT). The mouse was allowed to recover in its home cage. Seven days after stroke, when the necrosis of infarcted tissue at the stroke core has made a potential space for incorporating injected volumes [24] , cells, gel or cells encapsulated in gel were injected into the core of stroke. Cells were spun at 300 g for 5 minutes and re-suspended in PBS or HA gel premix (including gel ingredients without cross-linker) at 50,000 cells/µL (or 25,000 cells/µL for the experiment studying effects of cell concentration on HA gel resorption). To inject cells encapsulated in gels or gels alone the cross-linker was added and thoroughly mixed immediately before the gel mixture was withdrawn into a 25 µL Hamilton syringe (Hamilton Company, Reno, NV). Injections were conducted through a 30 G Hamilton needle into a point 0.6 mm below the surface of the brain.
Two µL of volume, was injected at 0.3 µL/mL rate. To study cell survival in C57BL/6 mice, animals were immunosuppressed with Tacrolimus (Cell Signaling, Danvers, MA). Four intraperitoneal injections of Tacrolimus (3mg/kg; dissolved in DMSO) were delivered for total of Tacrolimus (dissolved in 50% DMSO, 15% ethanol and 35% distilled water) was infused from a minipump (Model 1002; DURECT Corporation, Cupertico, CA). Minipumps were implanted subdermally between the scapulae and changed every two weeks. Upon minipump extraction a successful infusion of Tacrolimus was ensured by checking for any remaining Tacrolimus solution.
Additional subcutaneous injections of tacrolimus were administered on the day of pump replacement since it takes ~12hrs for miniosmotic pump to start infusion.
Magnetic Resonance Imaging of mice
Mice were anesthetized and placed in a small animal MRI (7T, Bruker BioSpin, Fremont, CA) 9 weeks after stroke. Respiratory rate was monitored throughout the procedure and body temperature was maintained at 37±0.5°C. A T2-weighted image set was acquired with the following parameters: rapid acquisition relaxation enhancement factor 8, repetition time 5300 milliseconds, echo time 15.00 milliseconds with an in-plane resolution of 0.039_0.039_0.50 mm with 13 contiguous slices. The MRI images were exported by the software ParaVision 5.1 (Bruker BioSpin, Fremont, CA) into a high-resolution file format (2DSEQ) and volumetric measurements were performed in ImageJ (National Institute of Health, Bethesda, MD). Gel area, which was represented as a T2 hyperintense signal in T2 sequence images, was quantified in all MRI images cut through lesion areas.
Tissue processing
Infarct size was determined 3-5 days after stroke by staining with a 2% triphenyl tetrazolium chloride (TTC; gr/mL, made in PBS; Sigma-Aldrich, St Louis, MO) solution for 40 minutes at 37°C. The brain was then cut in 1 mm sections using a mouse Brain Matrix (Zivic Instruments, Pittsburgh, PA) and imaged using a stereomicroscope. The same preparation was used to quantify hydrogel volume one day after injection. For immunohistochemical studies mice were euthanized at 2 weeks or 6 weeks after cell or gels or cells in gels injections and perfused with 4% paraformaldehyde (Fisher Scientific, Pittsburgh, PA; in PBS, pH: 7.4) and cryoprotected in sucrose for 48 hours. Brains were cut on cryostat at 16 µm intervals and mounted on gelatin-coated Superfrost ® slides (Fisher Scientific).
Immunohistochemistry
For transplant cell quantification, tissue sections were stained for HuNu, a human-specific nuclear antigen, using avidin-biotin complex (ABC) amplification (VECTASTAIN ® Elite ® ABC KitMouse IgG, Vector Laboratories, Burlingame, CA) and 3,3'-diaminobenzidine (DAB) labeling (ImmPACT™ DAB, Vector Laboratories) with blocking of endogenous biotin (Lab Vision™, Thermo Fisher Scientific, Fremont, CA). Immunofluorescence was performed using primary antibodies (Table S1 ) incubated overnight. HA gels were labelled for the biotin, and this was visualized using streptavidin tyramide signal amplification (TSA™, Life Technologies). All antibodies utilized are in Supplementary Table [54] .
Tissue analysis
Stroke volume was quantified in TTC-stained 1 mm brain sections by summing stroke areas multiplied by inter-slice distance of 1 mm. To measure vessel density inside transplants, slides were scanned with laser scanning confocal microscopy (C2 Series, Nikon Instruments Inc., Melville, NY), total length of vessels was measured by ImageJ and divided by volume of transplant computed as area multiplied by the section thickness. For colocalization studies the percentage of tissue volume in which GFP marker colocalized with a second marker was calculated in confocal image stacks using IMARIS software (Bitplane, South Windsor, CT).
Statistics
Tests were analyzed blindly to experimental condition. Animals were randomly assigned to control 
Results
Optimizing mechanical properties of HA gel in vivo
With the goal of injecting this gel into the stroke cavity, we identified the mechanical properties and gelation conditions that allowed the gel to fully flow into and fill the stroke cavity before gelation. HA gels with three different stiffness levels 100, 350 and 1000 Pa were injected in the stroke cavity ( Figure 1A , 1Bi-iii) one week after the stroke onset. This time point of injection was chosen as it corresponds to a period in which cell death in stroke is complete, and a clinical window in which patients might receive a stem cell/hydrogel therapy [2] . Twenty-four hours after the injection, both the intracerebral volume of gel and the remaining damaged tissue in the stroke area were measured. Both the 350 Pa and 1 kPa HA gels had significantly more volume of gel remaining in the brain (Figure 1Bvi ). However, the injected 350 Pa gel, which matches the mechanical properties of brain cortex [25] , was associated with the lowest remaining volume of infarcted tissue (Figure 1Bvii ), thus occupying the stroke cavity with the highest efficiency and establishing the most optimum gel-tissue interface. This greater expansion of the 350Pa gel and more complete occupation of the stroke cavity could be described because this gel matches the brain tissue's stiffness and leads to the gel conforming to stroke cavity boundaries and expelling, or compressing infarcted tissue. Therefore, the 350 Pa gel was chosen for the rest of the study.
Crosslinker sensitivity to MMPs in vivo
Hydrogel cross-linkers influence gel stability and degradation processes [26] . Stroke induces degradative enzyme, such as matrix metalloproteinaes (MMPs) [25] , that may serve to modify an injected hydrogel. Crosslinking motifs sensitive to MMPs were incorporated in the gel and compared to the hydrogel cross-linked with motifs insensitive to the enzymes. Two weeks after gel injection, mice were sacrificed and brain sections were stained for collagen (Figures 1Biv,   v) , a component of the vascular basement membrane [27] . While very few vessels were found in the MMP-insensitive condition (Figure 1Biv ), a significantly increased vascular in-growth was observed in the MMP-degradable gel (Figures 1Bv, viii) .
DOE approach to optimize the concentration of adhesion motifs and growth factors in vitro
Incorporating biochemical cues within hydrogel materials used for stem cell transplantation is an ideal approach to control survival and differentiation. However, there is a disconnect between the studies performed in vitro, which often utilize soluble differentiation cocktails to achieve differentiation, and the gels that are used in vivo. This is because either the precise control over an in vitro biochemical environment is not plausible in vivo, or a different in vivo differentiation outcome is observed despite of delivering the same in vitro growth factor cocktail. Our group recently showed that a statistical Design of Experiment (DOE) approach [21] can be used to optimize the concentration of adhesion motifs derived from laminin (IKVAV and YIGSR) and fibronectin (RGD) to promote the in vitro survival of iPS-NPCs and demonstrated that the optimal condition promoted neuronal differentiation [13] . Here we utilize the same DOE approach to optimize the concentration of brain-derived neurotrophic factor (BDNF) and bone morphogenic protein-4 (BMP-4) (both of which have potent effects on NPC differentiation [28] )
to promote survival in vitro and differentiation to different lineages in vivo. Human iPS-NPCs were used in these studies as these are a viable therapeutic candidate for a stem cell therapy in stroke [29] .
In order to increase retention of the growth factors by the hydrogel matrix in vivo, heparin was introduced to the HA backbone. Two separate DOE optimizations were performed using 
Effects of gel composition on brain tissue adjacent to the stroke
This step-by-step hydrogel optimization led to four candidates for in vivo testing: 1) an empty HA gel without any adhesion peptide or growth factor (HA) and astrocytic reaction to an injected scaffold [15] . C57BL/6 mice were injected with the four different gel conditions directly into the stroke cavity one week after the stroke onset and sacrificed two weeks later. Brain sections were stained for GFAP (astrocytes) and Iba1 (microglia) and compared with a non-injected stroke condition as a control. No significant difference was observed among all the conditions (Figure 2 ; [54] ), indicating that none of the HA groups induced a greater inflammatory or astrocytic response than the stroke insult itself.
HA gel degradation and angiogenesis
Timely degradation of bioscaffolds is of paramount importance in tissue engineering. To determine the contribution of transplanted iPS-NPCs vs. host tissue in degradation of HA gels over time, the gel optimized for highest cell survival, spreading and differentiation, HA Max, was chosen. The biotin-tagged gel was loaded with either 50,000 or 100,000 iPS-NPCs prior to transplantation into the stroke area of immunodeficient NSG mice one week after stroke. Two and six weeks later, the results showed that the gel loaded with 100,000 cells lost substantial volume between the two time points ( 
Effects of HA gel composition on human iPS-NPC proliferation and differentiation in vivo
To test the effect of the four distinct gels on iPS-NPC proliferation and differentiation after stroke, iPS-NPCs were transplanted into the stroke cavity of immunodeficient NSG mice 7 days after stroke. The NSG mouse strain was chosen to minimize the effects of host inflammation on in vivo cell proliferation and differentiation, as well as cell-scaffold interactions. Brain sections were stained for human nuclear antigen (HuNu) and the proliferation marker Ki67 at two and six weeks after transplantation, and double positive cells were counted ( Figure 3A,B) . To further study the effect of HA gels on glial differentiation as an alternative to neuronal differentiation of iPS-NPCs, tissue sections were stained for GFAP, expressed by both immature and mature astrocytes as well as NPCs, and S100b, mainly expressed by mature astrocytes [36] ( Figure 4A ). The ratio of GFP cells expressing only GFAP or both GFAP and S100b was quantified ( Figure 4B ). iPS-NPCs encapsulated in HA Max gels had a significantly increased expression of both GFAP and S100b markers compared with the other groups. In our experimental paradigm S100b staining is more confined to astrocyte identity in contrast to GFAP staining, associated with both astrocytes and also reported in NPCs. To distinguish between astrocytic differentiation vs. remaining in a precursor state, the ratio of GFP-GFAP-S100b over GFP-GFAP revealed that the majority of GFP cells expressing GFAP also express S100b. This confirms that encapsulation in HA Max gels promotes astrocytic differentiation of iPS-NPCs within the stroke cavity.
Effects of HA gels on cell survival in vivo
Previous studies have indicated poor cell survival when directly injected into or near the stroke cavity [37] . Yet, the stroke cavity is an attractive clinical transplant site because it is a cavity and can accept a large volume injection [3] and because it is directly adjacent to the site of the most substantial plasticity and recovery after stroke, the peri-infarct tissue [38] . In the preceding experiments, NSG mice were used so that prolonged immunosuppressive regimens would not be necessary and the focus would be on the hydrogel effects on transplant cell differentiation.
However, the deficient immune system of NSG mice allowed iPS-NPC survival equally in encapsulated and non-encapsulated cells ( Figures 3A and 4A , also quantified cell number; data not shown) likely because the inflammatory insult on transplanted cells was too weak to require protective effects of growth factors and adhesion motifs on graft survival. To study pro-survival effects of HA gels in a condition mimicking clinical situations we used single agent immunosuppression, an approach used in human stem cell transplant trials [39] , in C57Bl/6 wild type mice. Using GFP fluorescence quantification we found that encapsulating iPS-NPC in HA Max gel promoted survival two weeks after transplantation into the stroke cavity compared with non-encapsulated cells that appeared in very low numbers ( Figure 3C ). This indicates that in addition to controlling cell differentiation, HA gels promote survival in the early period after transplant. cells and matrix [6, 41] . However, the majority of these studies have attempted to maximize the benefit of combination therapies by either changing one unique aspect of the therapy while maintaining the other elements constant [42, 43] , by using a "presence/absence" binary evaluation of the matrix component [8, 44] , or by picking random concentrations (usually equimolar) for all the factors tested [42, 45] . The use of DOE allows systematic alteration of multiple components of the hydrogel to determine outcome characteristics for further in vivo testing.
Discussion
Tissue engineering in regenerative medicine requires overcoming complex control issues on two levels. The transplant itself exhibits a complex interaction with the recipient tissue and with adjoining transplant cells. Second, the recipient tissue has a complex structure and cell composition that makes tissue replacement challenging. Recently, studies have addressed transplant survival along with differentiation and repair of the recipient tissue with a data-driven statistical approach to optimize the gel composition to promote tissue repair. Many of these investigations have transitioned from in vitro to in vivo in the tissue-engineering field of organs such as retina [46] , skin [47] , liver [48] , digestive tract [49] , ear [50] , pancreas [51] , lungs [52] and skeletal muscle [53] . However the systematic development of a bioengineered scaffold for the brain with DOE studies has been rarely pursued past the in vitro stage [21, 22] . This work provides the first evidence supporting the multi-factorial cell/hydrogel/DOE approach that combines mechanical, biochemical and trophic factors to 1) systematically modify multiple factors at the same time, 2) identify the specific combination that promotes the desired cell behavior and 3) selectively control the in vivo distinct cell fate of transplanted cells. This works highlights the importance of interdisciplinary collaborations between engineers, clinicians, and biologists in the development of innovative cell transplantation therapies after stroke.
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